文献速递前列腺癌

PSMA-PET/CT引导的立体定向体部放疗治疗寡转移性前列腺癌:单中心经验与文献综述

Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
PubMed 文献 · BJU Int · 2019-09-11

本研究回顾性分析20例PSMA-PET/CT确诊的寡转移性前列腺癌患者,接受SABR后60%出现PSA下降,12个月局部无进展生存93%、远处无进展生存62%、无ADT生存70%。文献综述纳入4项研究共346例患者,2年局部无进展生存76-100%、远处无进展生存27-52%、无ADT生存58-62%。PSMA-PET/CT有助于识别真正寡转移患者并从SABR中获益。

要点

  • PSMA-PET/CT可识别真正寡转移前列腺癌患者,SABR后60%PSA下降。
  • 12个月局部无进展生存93%,远处无进展生存62%,无ADT生存70%。
  • 局部根治治疗与SABR间隔较长者远处无进展生存和无ADT生存更优。

核心结论

  • PSMA-PET/CT在识别真正寡转移性前列腺癌患者中具有重要作用,这些患者可能从SABR的转移灶定向治疗中最大获益。

研究设计与样本

  • 单中心回顾性队列研究,纳入前20例连续接受SABR的寡转移性前列腺癌患者。
  • 患者条件:根治性治疗后生化复发、无局部复发证据、未接受姑息性ADT、PSMA-PET/CT确认寡转移(≤3个病灶)。
  • SABR剂量:骨转移30 Gy分3次,淋巴结转移35-40 Gy分5次。
  • 文献综述纳入4项已发表研究,共346例患者。

主要发现

  • 本中心队列中12例(60%)SABR后PSA下降。
  • 1例局部进展,12个月局部无进展生存93%。
  • 10例出现SABR野外貌进展,12个月远处无进展生存62%。
  • 末次随访时6例(1例局部进展,5例远处进展)接受姑息性ADT,12个月无ADT生存70%。
  • 局部根治治疗与SABR间隔较长者远处无进展生存(P=0.03)和无ADT生存(P=0.005)更优。

关键数值与推荐

  • 文献综述中SABR后PSA下降报告率为60-70%。
  • 文献综述中2年局部无进展生存率76-100%,远处无进展生存率27-52%,无ADT生存率58-62%。

临床怎么用

  • PSMA-PET/CT可用于筛选真正寡转移性前列腺癌患者,指导SABR转移灶定向治疗。
  • 对根治性治疗后生化复发且PSMA-PET/CT确认≤3个转移灶的患者,可考虑SABR。

局限性

  • 单中心回顾性研究,样本量小(20例)。
  • 文献综述纳入研究数量有限(4项),异质性可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report the outcomes of stereotactic ablative body radiotherapy (SABR) in men with oligometastatic prostate cancer (PCa) diagnosed on prostate-specific membrane antigen (PSMA)-positron emission tomography/computed tomography (PET/CT), based on a single-institution experience and the published literature. PATIENTS AND METHODS: This was a retrospective cohort study of the first 20 consecutive men with oligometastatic PCa, treated with SABR in a single institution, who had biochemical recurrence after previous curative treatment (surgery/radiotherapy), had no evidence of local recurrence, were not on palliative androgen deprivation therapy (ADT), and had PSMA-PET/CT-confirmed oligometastatic disease (≤3 lesions). These men were treated with SABR to a dose of 30 Gy in three fractions for bone metastases, and 35-40 Gy in five fractions for nodal metastases. The outcomes of interest were: PSA response; local progression-free survival (LPFS); distant progression-free survival (DPFS); and ADT-free survival (ADTFS). A literature review was performed to identify published studies reporting on outcomes of PSMA-PET/CT-guided SABR. RESULTS: In our institutional cohort, 12 men (60%) had a decline in PSA post-SABR. One man had local progression 9.6 months post-SABR, with 12-month LPFS of 93%. Ten men had distant progression outside of their SABR treatment field, confirmed on PSMA-PET/CT, with 12-month DPFS of 62%, of whom four were treated with palliative ADT, two received prostate bed radiotherapy for prostate bed progression (confirmed on magnetic resonance imaging), and four received a further course of SABR (of whom one had further progression and was treated with palliative ADT). At last follow-up, six men (one with local progression and five with distant progression) had received palliative ADT. The 12-month ADTFS was 70%. Men with longer intervals between local curative treatment and SABR had better DPFS (P = 0.03) and ADTFS (P = 0.005). Four additional studies reporting on PSMA-PET/CT-guided SABR for oligometastatic PCa were identified and included in the review, giving a total of 346 patients. PSA decline was reported in 60-70% of men post-SABR. The 2-year LPFS, DPFS and ADTFS rates were 76-100%, 27-52%, and 58-62%, respectively. CONCLUSION: Our results showed that PSMA-PET/CT could have an important role in identifying men with true oligometastatic PCa who would benefit the most from metastases-directed therapy with SABR.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ong WL, Koh TL, Lim Joon D, et al. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. BJU Int. 2019. PMID: 31507035. doi:10.1111/bju.14886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。